<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35087">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02649790</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-8602-801</org_study_id>
    <nct_id>NCT02649790</nct_id>
  </id_info>
  <brief_title>Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma</brief_title>
  <official_title>Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients With Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, multi-center, open-label clinical study with separate dose
      escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety,
      tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in patients
      with relapsed/refractory MM.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate dose limiting toxicities of KPT-8602</measure>
    <time_frame>From first dose through Cycle 1- 28 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">116</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>KPT-8602</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg starting dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KPT-8602</intervention_name>
    <arm_group_label>KPT-8602</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Evidence of disease progression:

               -  Symptomatic relapsed or refractory requiring current treatment.

               -  Previously treated with ≥ 3 prior regimens (lines of therapy) that included at
                  least one of each of the following: alkylating agent, immunomodulatory drug,
                  proteasome inhibitor, and a steroid.

               -  Must be refractory to most recent anti-cancer regimen.

          -  Must have measurable disease defined by one of the following:

               -  Serum M-protein ≥ 0.5 g/dL by serum protein electrophoresis (SPEP) or for IgA
                  myeloma, by quantitative IgA. If SPEP is felt to be unreliable for routine
                  Mprotein measurement (e.g., for patients with IgA MM), then quantitative Ig
                  levels by nephelometry or turbidometry are acceptable; or

               -  Urinary M-protein excretion at least 200 mg/24 hours; or

               -  Serum Free Light Chain (Serum FLC) whereby the involved light chain measures ≥
                  10 mg/dL and with an abnormal ratio.

          -  Eastern Cooperative Oncology Group performance status of ≤ 1.

        Exclusion Criteria

          -  Time since the last prior therapy:

               -  Radiation, chemotherapy, immunotherapy or any other anticancer therapy,
                  including investigational anticancer therapy ≤ 2 weeks prior to Cycle 1 Day 1.

               -  Palliative steroids for disease related symptoms are allowed up to 3 days prior
                  to Cycle 1 Day 1.

          -  Active graft versus host disease after allogeneic stem cell transplantation. At least
             3 months must have elapsed since completion of allogeneic stem cell transplantation.

          -  Active central nervous system malignancy. Patients who have only had prophylactic
             intrathecal or intravenous chemotherapy against central nervous system disease are
             eligible.

          -  Patients with significantly diseased or obstructed gastrointestinal tract or
             uncontrolled vomiting or diarrhea that could interfere with the absorption of
             KPT-8602.

          -  Prior exposure to XPO1 inhibitors.

          -  Life expectancy of ≥ 4 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Kauffman, M.D., Ph.D.</last_name>
    <email>mkauffman@karyopharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sharon Shacham, PhD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachid Baz, MD</last_name>
      <phone>813-745-8212</phone>
      <email>Rachid.Baz@Moffit.org</email>
    </contact>
    <investigator>
      <last_name>Rachid Baz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack UMC</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josh Richter, MD</last_name>
      <phone>551-996-8704</phone>
      <email>JRicter@HackensackUMC.org</email>
    </contact>
    <investigator>
      <last_name>Josh Richter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adriana Rossi, MD</last_name>
      <phone>646-962-6500</phone>
      <email>adr9009@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Adriana Rossi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University, The James Cancer Hospital and Solove Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Hofmeister, MD</last_name>
      <email>Craig.hofmeister@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Hofmeister, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Abramson Cancer Center Clinical Research Unit</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Vogl, MD</last_name>
      <phone>215-614-0037</phone>
      <email>Dan.Vogl@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Dan Vogl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Cornell, MD,MS</last_name>
      <phone>615-936-8422</phone>
      <email>robert.f.cornell@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Cornell, MD,MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Chen, MD, MHPE, FRCPC</last_name>
      <phone>416-946-4501</phone>
      <email>Christine.Chen@uhn.edu</email>
    </contact>
    <investigator>
      <last_name>Christine Chen, MD, MHPE, FRCPC</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUHC GLEN Site Cedars - Cancer Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chaim Chustik, MD</last_name>
      <phone>514-934-1558</phone>
      <email>chaim.shustik1@mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Chaim Shustik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 31, 2017</lastchanged_date>
  <firstreceived_date>January 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>KPT-8602</keyword>
  <keyword>MM</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Relapsed/refractory Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
